Free Trial

10 Best Small Cap Stocks to Buy Now

Let's talk about small cap stocks. It's common knowledge that tilting your stock portfolio toward smaller-capitalization companies will generally outperform the S&P 500 over a long enough period of time. Companies that have a market value between $300 million and $2 billion tend to outperform their large cap counterparts simply because they have a lot more room to grow and haven't saturated their markets yet.

While small cap stocks provide some of the best growth opportunities in public markets, they are also much more volatile than their large cap counterparts. Many large cap companies that are name brands among retail investors (Apple, Tesla, etc.) move in unison with the total direction of the market.

It's a different situation with small cap stocks. There are clear winners and losers over the course of the year. Price performance is much more dependent on a small cap's stock performance (earnings per share) and how much interest there is in the company among retail investors. If a small cap stock has strong earnings and gains a following on sites like Seeking Alpha and MarketBeat, they can see their stock price double or triple over the course of a year. That typically doesn't happen with their large cap counterparts.

How do you find the winners though? Sure, you can buy a small cap index ETF and get average returns and you'll do fine over the course of time. But, what if there was a way to identify the best small caps to buy now without having a crystal ball? It's impossible to say with certainty what the best performing small cap stocks will be next year, but we polled the most-accurate and best-performing research analysts on Wall Street to see what they have to say.

Wall Street analysts publish more than 48,000 research notes on small cap companies each year. We've compiled a list of the 10 stocks that they are consistently issuing "buy", "strong buy", and "conviction buy" ratings on.

#1 - LSI Industries (NASDAQ:LYTS)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$20.33 (26.3% Upside)

About LSI Industries

LSI Industries logoLSI Industries Inc produces and sells non-residential lighting and retail display solutions in the United States, Canada, Mexico, and Latin America. It operates through two segments, Lighting and Display Solutions. The Lighting segment manufactures, markets, and sells non-residential outdoor and indoor lighting fixture and control solutions in the commercial and industrial markets. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/26/2024Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
8/18/2023Craig HallumBoost Price TargetBuy ➝ Buy$21.00 ➝ $23.00
8/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
1/27/2023HC WainwrightBoost Price TargetBuy$16.50 ➝ $20.00
1/27/2023Canaccord Genuity GroupBoost Price TargetBuy$12.00 ➝ $16.00
1/9/2023Craig HallumInitiated CoverageBuy$18.00
11/4/2022Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.00
10/21/2022Canaccord Genuity GroupReiterated RatingBuy$9.00
1/28/2022HC WainwrightReiterated RatingBuy


#2 - CPI Card Group (NASDAQ:PMTS)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$35.50 (16.7% Upside)

About CPI Card Group

CPI Card Group logoCPI Card Group Inc, together with its subsidiaries, engages in the design, production, data personalization, packaging, and fulfillment of financial payment cards. It operates through Debit and Credit, and Prepaid Debit segments. The Debit and Credit segment produces financial payment cards and provides integrated card services to card-issuing financial institutions. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/23/2024Roth CapitalReiterated RatingBuy
2/23/2024Roth MkmInitiated CoverageBuy$40.00
9/18/2023B. RileyInitiated CoverageBuy$31.00
3/9/2023Lake Street CapitalBoost Price Target$42.00 ➝ $49.00


#3 - Superior Group of Companies (NASDAQ:SGC)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$23.00 (11.9% Upside)

About Superior Group of Companies

Superior Group of Companies logoSuperior Group of Companies, Inc manufactures and sells apparel and accessories in the United States and internationally. It operates through three segments: Branded Products, Healthcare Apparel, and Contact Centers. The Branded Products segment produces and sells customized merchandising solutions, promotional products, and branded uniform to chain retailer, food service, entertainment, technology, transportation, and other industries under BAMKO and HPI brands. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/24/2024DA DavidsonReiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
6/4/2024DA DavidsonInitiated CoverageBuy$24.00
5/28/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$22.00 ➝ $22.00
5/10/2024Barrington ResearchBoost Price TargetOutperform ➝ Outperform$18.00 ➝ $22.00
3/19/2024Singular ResearchReiterated RatingBuy
3/15/2024Barrington ResearchBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $18.00
9/28/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$13.00
8/9/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$17.00 ➝ $13.00
3/28/2023Barrington ResearchLower Price TargetOutperform$19.00 ➝ $17.00
3/17/2023EF Hutton Acquisition Co. ILower Price TargetBuy$20.00 ➝ $18.00


#4 - GeoVax Labs (NASDAQ:GOVX)

Consensus Rating
Strong Buy
Rating Score
3.5
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$14.00 (434.4% Upside)

About GeoVax Labs

GeoVax Labs logoGeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/23/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
7/16/2024Roth CapitalUpgradeStrong-Buy
7/16/2024Roth MkmInitiated CoverageBuy$20.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/18/2024HC WainwrightBoost Price TargetBuy ➝ Buy$8.00 ➝ $120.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00
3/24/2023HC WainwrightReiterated RatingBuy$120.00
3/3/2023Dawson JamesInitiated CoverageBuy$60.00


#5 - Tectonic Therapeutic (NASDAQ:TECX)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$62.50 (254.3% Upside)

About Tectonic Therapeutic

Tectonic Therapeutic logoAvrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/24/2024Leerink PartnrsUpgradeStrong-Buy
7/24/2024SVB LeerinkInitiated CoverageOutperform$49.00
6/26/2024Piper SandlerInitiated CoverageOverweight$76.00
6/24/2024TD CowenInitiated CoverageBuy


#6 - TerraVest Industries (TSE:TVK)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
C$91.67 (12.2% Upside)

About TerraVest Industries

TerraVest Industries logoTerraVest Industries Inc manufactures and sells goods and services to energy, agriculture, mining, transportation, and other markets in Canada and the United States. It operates through four segments: Home Heating and Cooling Products (HVAC Equipment); Compressed Gas Storage and Distribution Equipment (Compressed Gas Equipment); Energy Processing Equipment (Processing Equipment); and Service. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/15/2024National BanksharesSet Price TargetOutperformC$89.00
7/14/2024National Bank FinancialUpgradeStrong-Buy
7/4/2024DesjardinsSet Price TargetBuyC$95.00
6/10/2024Canaccord Genuity GroupSet Price TargetBuyC$91.00


#7 - Bioceres Crop Solutions (NASDAQ:BIOX)

Consensus Rating
Buy
Rating Score
3.4
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$19.00 (71.9% Upside)

About Bioceres Crop Solutions

Bioceres Crop Solutions logoBioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/19/2024Canaccord Genuity GroupUpgradeStrong-Buy
7/19/2024Canaccord Genuity GroupReiterated RatingBuy$17.00
7/2/2024Roth CapitalUpgradeStrong-Buy
7/2/2024Roth MkmInitiated CoverageBuy$15.00
2/9/2024Roth MkmBoost Price TargetBuy ➝ Buy$20.00 ➝ $21.00
11/1/2023Roth MkmLower Price TargetBuy ➝ Buy$31.00 ➝ $20.00
9/12/2023Roth MkmReiterated RatingBuy ➝ Buy$31.00
9/12/2023Lake Street CapitalLower Price TargetBuy ➝ Buy$30.00 ➝ $25.00
8/16/2023Roth MkmReiterated RatingBuy ➝ Buy$31.00
4/5/2023OppenheimerInitiated CoverageOutperform$15.00


#8 - Coca-Cola FEMSA (NYSE:KOF)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
5 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$99.55 (13.5% Upside)

About Coca-Cola FEMSA

Coca-Cola FEMSA logoCoca-Cola FEMSA, SAB. de C.V., a franchise bottler, produces, markets, sells, and distributes Coca-Cola trademark beverages. The company offers sparkling beverages, including colas and flavored sparkling beverages; and waters and other beverages, such as juice drinks, coffee, teas, milk, value-added dairy products, sports and energy drinks, alcoholic beverages, and plant-based drinks. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/15/2024BarclaysLower Price TargetOverweight ➝ Overweight$115.00 ➝ $105.00
7/10/2024UBS GroupLower Price TargetBuy ➝ Buy$112.00 ➝ $102.00
4/16/2024UBS GroupBoost Price TargetBuy ➝ Buy$109.00 ➝ $112.00
4/12/2024JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$102.00 ➝ $107.00
4/12/2024ScotiabankUpgradeSector Perform ➝ Sector Outperform
2/2/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$89.00 ➝ $102.00
1/12/2024UBS GroupUpgradeNeutral ➝ Buy$83.00 ➝ $109.00
12/7/2023CitigroupInitiated CoverageNeutral$90.00
12/4/2023Jefferies Financial GroupInitiated CoverageBuy$100.57
8/17/2023JPMorgan Chase & Co.Lower Price TargetNeutral ➝ Neutral$91.00 ➝ $90.00


#9 - Q32 Bio (NASDAQ:QTTB)

Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$62.25 (71.8% Upside)

About Q32 Bio

Q32 Bio logoQ32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/17/2024GuggenheimInitiated CoverageBuy$100.00
5/21/2024Leerink PartnrsUpgradeStrong-Buy
5/21/2024SVB LeerinkInitiated CoverageOutperform$54.00
4/11/2024OppenheimerInitiated CoverageOutperform$50.00
4/2/2024Piper SandlerInitiated CoverageOverweight$45.00


#10 - Gauzy (NASDAQ:GAUZ)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$21.75 (111.6% Upside)

About Gauzy

Gauzy logoGauzy Ltd. is a fully-integrated light and vision control company which focused on the research, development, manufacturing and marketing of vision and light control technologies. It operates principally in Germany, France, the United States, Canada, China, Singapore and Dubai. Gauzy Ltd. is headquartered in Tel Aviv, Israel.
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/2/2024B. RileyInitiated CoverageBuy$21.00
7/1/2024B. RileyUpgradeStrong-Buy
7/1/2024BarclaysInitiated CoverageOverweight$24.00
7/1/2024Stifel NicolausInitiated CoverageBuy$18.00
7/1/2024TD CowenInitiated CoverageBuy$24.00


More Investing Slideshows:

Collapse of the Petrodollar (Ad)

The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.

In answer to this issue, we have released a Special Report to the public.